Kista, Sweden, February 22, 2019 – Chordate Medical Holding AB's (publ) ("Chordate"), a specialty medtech company that focuses on developing and commercializing neuromodulating treatment systems for treating non-allergic rhinitis and chronic migraine, today announced the decision to conduct an interim analysis of the ongoing clinical study with Chordate's investigative product Kinetic Oscillation Stimulation System S211 (K.O.S-treatment).  The multicenter study conducted in Germany enrolls patients with diagnosed chronic migraine (15 days/month of headache, whereof >8 days with migraine).

"We have come to the point in the development of this study where it makes sense to – by common praxis – verify the validity of the underlying statistical calculations of needed study population, and to determine probability of its outcome. Chronic headache problems concern many patients around the world. We are continuing to explore what we believe can offer a great potential for remedy with our proprietary non-pharmaceutical preventive treatment method", said Anders Weilandt, CEO of Chordate.

The randomized, placebo-controlled, double-blind, multicenter study is being conducted at four neurology clinics in Germany. The study intends to enroll up to 140 subjects and is designed to evaluate the efficacy and safety of the K.O.S-treatment, with the primary endpoint to detect mean change from baseline (4-week screening period) in monthly headache days with moderate to severe intensity, in a 4-week performance assessment period. The fifty percent of the patients in the K.O.S arm are receiving active treatment from the S211, while the other half of the patients are receiving a validated sham/placebo treatment from the same equipment.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77 

Information:
This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact person above for publication on February 22, 2019 at. 08:30 CET.

The following documents can be retrieved from beQuoted
Chordate Pressrelease 2019-02-22 English.pdf

Chordate Pressrelease 2019-02-22 English.pdf

"We have previously communicated that we will initially target the Nordic, UK and the Middle East, which are mature markets. It is gratifying that we now can increase presence in UK and Ireland together with a strong company like the Severn. For a long time, Chordate has focused on UK, including through our major international rhinitis study where three British university hospitals are involved. However, we see that the marketing efforts needs to be considerably more aggressive. With Severn as a partner, we would gain access to experienced persons from a strong ENT company, which we believe will enable us to reach Chordate's full potential in the UK and Irish markets, "says Anders Weilandt, CEO of Chordate.

Transition to Severn will take place in the third quarter of 2018.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

Information: This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided through the contact of the above contact person for publication on August 14, 2018 at. 08:30 CET.

The following documents can be retrieved from beQuoted
Chordate Pressrelease 2018-08-14 English.pdf

PDF

" Chordate and Nanos Medical represents together a strong combination of patented technology and efficient market access competence. This long-term cooperation gives us a central position in the Chinese ear-nose-throat market (ENT), and freedom for Chordate to be focusing its own resources on building further market presence, primarily in the EU. Being able to take such a big and important step early in our international commercialization, is something that I deem as extremely valuable to our company," says Anders Weilandt, CEO of Chordate.

"Nanos Medical has ENT and cardio-vascular technology as the primary focus. Chordate's treatment method and product system is now added to our strong offer within ENT, where we already have well established channels. Initially we shall successfully manage the product registration process of Chordate's product in China, and parallel to that secure the production capacity, as well as important customer contacts to ensure a quick market introduction. We are looking forward to make this cooperation with Chordate into a great success for both parties, and for our respective shareholders," says Nanos Medical's CEO, Terry Cui.

Kista-Shanghai, 24 May 2018

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

Terry Cui, CEO
terry@nanosmedical.com 
Phone: +86 (0) 21- 60433667

Information:
This information is such information that Chordate Medical Holding AB (publ) is required to disclose under the EU market abuse regulation. The information was provided, through the contact person above, for publication on the 24 May 2018 At. 15:45 CET.

The following documents can be retrieved from beQuoted
Chordate Pressrelease 2018-05-24 English.pdf

PDF

Data Anticipated Q4 2019
Kista, Sweden, May 08, 2018 – Chordate Medical Holding AB's (publ) ("Chordate"), a specialty medtech company that focuses on developing and commercializing neuromodulating treatment systems for treating non-allergic rhinitis and migraine, today announced that the first patients were enrolled in Chordate's clinical study of its Kinetic Oscillation Stimulation System S101 (KOS-treatment), an investigative product, in patients with diagnosed chronic non-allergic rhinitis.

"To now get started with the first patients at the University Hospitals in Helsinki and Kuopio, Finland, is very important in our long-term securing of scientific evidence. We know from previous studies, and our own and others' clinical experiences in practice, that we make significant difference for this very large patient group. We are now building further on this with the aim to produce a clear scientific basis for our continued business journey", says Anders Weilandt, CEO of Chordate.

The randomized, placebo-controlled, double-blind, multicenter study is being conducted at fourteen ENT university clinics in Finland, UK, The Netherlands, Italy and the Czech Republic. Coordinating investigator is Professor Claire Hopkins at Guys Hospital, London and study advisor is Professor Mats Holmström at the Karolinska Institute, Stockholm. The study intends to enroll up to 300 subjects and is designed to evaluate the efficacy and safety of the KOS-treatment. The primary endpoint is to detect weekly median change in a set of evaluation criteria from baseline, with a series of two consecutive treatments, until the third month follow-up visit. The total follow-up period of each patient is twelve months. Patients in the KOS arm will receive active treatment from the S101, while patients receiving placebo treatment will be given a validated sham treatment from the same equipment.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com 
Phone: +46 (0) 733 87 42 77

Information:
This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact person above for publication on May 08, 2018 at. 14:45 CET.

The following documents can be retrieved from beQuoted
Chordate Pressrelease 2018-05-08 English.pdf

PDF

"Enrolling the first patient in our multicenter migraine study marks an important milestone for the company as we work our way towards bringing our S211 product to the market. I believe that our proprietary non- pharmaceutical preventive treatment method has great potential to make huge difference for many patients with chronic headache problems around the world", said Anders Weilandt, CEO of Chordate.

The randomized, placebo-controlled, double-blind, multicenter study is being conducted at four neurology clinics in Germany. The study intends to enroll up to 140 subjects and is designed to evaluate the efficacy and safety of the KOS-treatment, with the primary endpoint to detect mean change from baseline (4-week screening period) in monthly headache days with moderate to severe intensity, in a 4-week performance assessment period. Patients in the KOS arm will receive active treatment from the S211, while patients receiving placebo treatment will be given a validated sham treatment from the same equipment.

Kista, Sweden, March 23, 2018

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

Information:
This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact person above for publication on March 23, 2018 at. 08:30 CET.

The following documents can be retrieved from beQuoted
Chordate Pressrelease 2018-03-23 English.pdf

PDF

"We have a CE-marked and proven product system that currently is launched in the markets we can finance and manage, as stated earlier. Nanos Medical represents a fast growing and financially strong partner who immediately can start market preparations based on our eight Chinese patents. The joint venture adds resources and regional know-how that we cannot deploy ourselves, for the time being. This is in my opinion a big step for Chordate, "said Anders Weilandt, CEO of Chordate.

"Nanos Medical has ear-nose-throat (ENT) and cardiovascular medicine as focus areas. Chordate's treatment method and product system fits well into our business model, and will strengthen our range within ENT where we have already established marketing channels. We are very familiar with the product registration process in China, and have the required production capacity available. We look forward to implementing an efficient marketing process and rapid launch, as we consider this to be an important addition to our product portfolio", says Nanos Medical's CEO Terry Cui.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77 

Terry Cui, CEO
terry@nanosmedical.com
Phone: +86 (0) 21- 60433667 

Information: 
This information is information that Chordate Medical Holding AB (publ.) is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on 18th December 2017 at. 08:30 CET.

The following documents can be retrieved from beQuoted
Chordate Pressrelease 2017-12-18 English.pdf

PDF